Moleculin Biotech Inc (NASDAQ:MBRX) concluded the trading at $1.77 on Wednesday, February 19 with a fall of -7.81% from its closing price on previous day.
Considering stock’s 52-week price range provides that MBRX hit a high price of $10.35 and saw its price falling to a low level of $0.40 during that period. Over a period of past 1-month, stock came subtracting -5.85% in its value.
With its current market valuation of $7.36 million, Moleculin Biotech Inc is set to declare its quarterly results in March. Analysts are in estimates of 0 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -14.09 for current year with estimates of that growing to -5.28 in next year.
In contrast, when we review MBRX stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 100% Sell for it.
Digging deeper we become aware of the PEG ratio of the MBRX stock which is currently positioned at 0. It further provides that stock’s current price level is 30.27% away from its 20-day simple moving average and is 3.14% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 55.69 while volatility remained at 137.84% over the past week which changes to 43.11% when measuring it over the past month. Beta is valued at 1.94, while measure of average true range or ATR is currently at 0.49.
The percentage of outstanding shares held by the insiders is 3.14% while it is 11.18% for the institutional holders. Addition of 4.12% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
